Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

By S. Daigle, E. Olhava, Carly A. Therkelsen, A. Basavapathruni, Lei Jin, P. Boriack-Sjodin, C. Allain, C. Klaus, Alejandra Raimondi, M. Scott and 6 more. Blood, 2013

684 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/64a6050c839f3e00445eb9b4adea1136dcb265b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ping Gao
2. Huafeng Zhang
3. Linchong Sun

Citations in the corpus

• Metabolic reprogramming and epigenetic modifications on the path to cancer (2021, background): “By occupying the SAMbinding pocket and inducing conformational changes in DOT1L, EPZ-5676, a derivative of EPZ004777, is another effective DOT1L inhibitor that led to tumor regression in rat xenograft models of MLL-rearranged leukemia (Daigle et al., 2013).”
• Transcriptional Addiction in Cancer (2017, neutral): “These leukemias are especially vulnerable to genetic and chemical perturbation of DOT1L, and DOT1L inhibitors are now in clinical trials for these malignancies (Daigle et al., 2013).”